1
|
Bühler MM, Kulis M, Duran‐Ferrer M, Clot G, Nadeu F, Navarro A, López C, Giné E, Beà S, Campo E, Martín‐Subero JI. A SIMPLE EPIGENETIC SIGNATURE DEFINES TWO BIOLOGIC GROUPS OF MANTLE CELL LYMPHOMA. Hematol Oncol 2021. [DOI: 10.1002/hon.58_2879] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Affiliation(s)
- M. M. Bühler
- Hospital Clínic Barcelona IDIBAPS Barcelona Spain
| | - M. Kulis
- Hospital Clínic Barcelona IDIBAPS Barcelona Spain
| | | | - G. Clot
- Hospital Clínic Barcelona IDIBAPS Barcelona Spain
| | - F. Nadeu
- Hospital Clínic Barcelona IDIBAPS Barcelona Spain
| | - A. Navarro
- Hospital Clínic Barcelona IDIBAPS Barcelona Spain
| | - C. López
- Hospital Clínic Barcelona IDIBAPS Barcelona Spain
| | - E. Giné
- Hospital Clínic Barcelona IDIBAPS Barcelona Spain
| | - S. Beà
- Hospital Clínic Barcelona IDIBAPS Barcelona Spain
| | - E. Campo
- Hospital Clínic Barcelona IDIBAPS Barcelona Spain
| | | |
Collapse
|
2
|
Rivas‐Delgado A, López C, Nadeu F, Grau M, Rivero A, Bosch J, Alcoceba M, Gustavo T, Luizaga L, Barcena C, Kelleher N, Martin S, Mozas P, Balague O, Frigola G, Magnano L, Baumann T, Villamor N, Muntañola A, Sancho JM, García‐Sancho AM, Gonzalez‐Barca E, Climent F, Campo E, Giné E, López‐Guillermo A, Beà S. TESTICULAR DIFFUSE LARGE B‐CELL LYMPHOMA: CLINICO‐BIOLOGICAL CHARACTERIZATION, EVALUATION OF TREATMENT RESPONSE AND SURVIVAL. Hematol Oncol 2021. [DOI: 10.1002/hon.15_2880] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Affiliation(s)
- A. Rivas‐Delgado
- Hospital Clínic de Barcelona Hematology and Pathology Departments Barcelona Spain
| | - C. López
- Instituto de Investigaciones Biomédicas August Pi i Sunyer (IDIBAPS) Molecular pathology of lymphoid neoplasms Barcelona Spain
| | - F. Nadeu
- Instituto de Investigaciones Biomédicas August Pi i Sunyer (IDIBAPS) Molecular pathology of lymphoid neoplasms Barcelona Spain
| | - M. Grau
- Instituto de Investigaciones Biomédicas August Pi i Sunyer (IDIBAPS) Molecular pathology of lymphoid neoplasms Barcelona Spain
| | - A. Rivero
- Hospital Clínic de Barcelona Hematology and Pathology Departments Barcelona Spain
| | - J. Bosch
- Hospital de Bellvitge IDIBELL Pathology Department Barcelona Spain
| | - M. Alcoceba
- Hospital Universitario de Salamanca Hematology Department Salamanca Spain
| | - T. Gustavo
- ICO‐IJC‐Hospital Universitari Germans Trias i Pujol Hematology and Pathology Departments Badalona Spain
| | - L. Luizaga
- Hospital Universitari Mutua de Terrassa Hematology and Pathology Departments Terrasa Spain
| | - C. Barcena
- Hospital Universitario 12 de Octubre Hematology and Pathology Departments Madrid Spain
| | - N. Kelleher
- Institut Català d'Oncologia‐Hospital de Palamos Hematology Department Girona Spain
| | - S. Martin
- Instituto de Investigaciones Biomédicas August Pi i Sunyer (IDIBAPS) Molecular pathology of lymphoid neoplasms Barcelona Spain
| | - P. Mozas
- Hospital Clínic de Barcelona Hematology and Pathology Departments Barcelona Spain
| | - O. Balague
- Hospital Clínic de Barcelona Hematology and Pathology Departments Barcelona Spain
| | - G. Frigola
- Hospital Clínic de Barcelona Hematology and Pathology Departments Barcelona Spain
| | - L. Magnano
- Hospital Clínic de Barcelona Hematology and Pathology Departments Barcelona Spain
| | - T. Baumann
- Hospital Universitario 12 de Octubre Hematology and Pathology Departments Madrid Spain
| | - N. Villamor
- Hospital Clínic de Barcelona Hematology and Pathology Departments Barcelona Spain
| | - A. Muntañola
- Hospital Universitari Mutua de Terrassa Hematology and Pathology Departments Terrasa Spain
| | - J. M. Sancho
- ICO‐IJC‐Hospital Universitari Germans Trias i Pujol Hematology and Pathology Departments Badalona Spain
| | | | - E. Gonzalez‐Barca
- Institut Català d’Oncologia‐Hospital Duran i Reynals IDIBELL Universitat de Barcelona Hematology Department L'Hospitalet de Llobregat Spain
| | - F. Climent
- Hospital de Bellvitge IDIBELL Pathology Department Barcelona Spain
| | - E. Campo
- Instituto de Investigaciones Biomédicas August Pi i Sunyer (IDIBAPS) Molecular pathology of lymphoid neoplasms Barcelona Spain
| | - E. Giné
- Hospital Clínic de Barcelona Hematology and Pathology Departments Barcelona Spain
| | - A. López‐Guillermo
- Hospital Clínic de Barcelona Hematology and Pathology Departments Barcelona Spain
| | - S. Beà
- Instituto de Investigaciones Biomédicas August Pi i Sunyer (IDIBAPS) Molecular pathology of lymphoid neoplasms Barcelona Spain
| |
Collapse
|
3
|
Búa BR, Jiménez‐Ubieto A, Blanco JJS, Abrisqueta P, Gutiérrez A, Ramírez‐Páyer Á, Giné E, Etxetxipia IZ, Terol MJ, Cruz FDL, Andreu R, Ramírez M, Fuente ADL, Viguria M, Peñarrubia M, Grande C, Montes‐Moreno S, Barrigón MDC, García‐Sancho AM. UPDATED RESULTS OF A PHASE 2 STUDY FROM GELTAMO INVESTIGATING THE COMBINATION OF IBRUTINIB WITH R‐GEMOX IN PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA. Hematol Oncol 2021. [DOI: 10.1002/hon.94_2880] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Affiliation(s)
- B. Rey Búa
- Hospital Universitario de Salamanca and IBSAL Hematology Department Salamanca Spain
| | | | | | - P. Abrisqueta
- Hospital Vall d’Hebron Hematology Department Barcelona Spain
| | - A. Gutiérrez
- H. Son Espases Hematology Department Palma de Mallorca Spain
| | | | - E. Giné
- H. Clinic de Barcelona Hematology Department Barcelona Spain
| | - I. Zeberio Etxetxipia
- Hospital Universitario de Donostia Hematology Department Donostia‐San Sebastian Spain
| | | | - F. de la Cruz
- Hospital Virgen del Rocio Hematology Department Sevilla Spain
| | - R. Andreu
- Hospital la Fe Hematology Department Valencica Spain
| | - M. Ramírez
- H. Especialidades Jerez de la Frontera Hematology Department Jerez Spain
| | | | - M. Viguria
- Complejo Hospitalario de Navarra Hematology Department Pamplona Spain
| | - M. Peñarrubia
- Hospital Clínico Universitario de Valladolid Hematology Department Valladolid Spain
| | - C. Grande
- Hospital 12 de Octubre Hematology Department Madrid Spain
| | - S. Montes‐Moreno
- H. Universitario Marqués de Valdecilla Pathology Department Santander Spain
| | | | | |
Collapse
|
4
|
Muntañola A, Magnano L, Mercadal S, Huguet M, Bobillo S, Bastos‐Oreiro M, Jiménez‐Ubieto A, Rovira J, Rivero A, Alcoceba M, Mozas P, Luizaga L, Alonso‐Álvarez S, Rivas‐Delgado A, Giné E, Caballero D, Sancho JM, López‐Guillermo A. OUTCOME OF 133 PATIENTS WITH FOLLICULAR LYMPHOMA (FL) PROGRESSING BEFORE 24 MONTHS (POD24) AFTER IMMUNOCHEMOTHERAPY: A GELTAMO STUDY. Hematol Oncol 2021. [DOI: 10.1002/hon.27_2880] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Affiliation(s)
- A. Muntañola
- Hospital Universitari Mútua Terrassa Hematology Barcelona Spain
| | - L. Magnano
- Hospital Clínic Barcelona Hematology Barcelona Spain
| | - S. Mercadal
- Hospital Duran Reynals ‐ ICO Hospitalet Hematology Barcelona Spain
| | - M. Huguet
- Hospital Germans Trias i Pujol ‐ ICO Badalona Hematology Barcelona Spain
| | - S. Bobillo
- Hospital Vall d'Hebron Hematology Barcelona Spain
| | | | | | - J. Rovira
- Hospital Universitari Joan XXIII ‐ ICO Tarragona Hematology Tarragona Spain
| | - A. Rivero
- Hospital Clínic Barcelona Hematology Barcelona Spain
| | - M. Alcoceba
- Hospital Universitario de Salamanca Molecular Biology Salamanca Spain
| | - P. Mozas
- Hospital Clínic Barcelona Hematology Barcelona Spain
| | - L. Luizaga
- Hospital Universitari Mútua Terrassa, Pathology Barcelona Spain
| | | | | | - E. Giné
- Hospital Clínic Barcelona Hematology Barcelona Spain
| | - D. Caballero
- Complejo Asistencial Universitario de Salamanca /IBSAL Hematology Salamanca Spain
| | - J. M. Sancho
- Hospital Germans Trias i Pujol ‐ ICO Badalona Hematology Barcelona Spain
| | | |
Collapse
|
5
|
Tarragon E, Calleja-Conde J, Giné E, Segovia-Rodríguez L, Durán-González P, Echeverry-Alzate V. Alcohol mixed with energy drinks: what about taurine? Psychopharmacology (Berl) 2021; 238:1-8. [PMID: 33175215 DOI: 10.1007/s00213-020-05705-7] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/30/2020] [Accepted: 11/04/2020] [Indexed: 01/31/2023]
Abstract
RATIONALE Since energy drinks (EDs) were marketed to the general public as recreational and soft drinks, mixing these with alcohol has become a popular practice, especially in the younger population. Alcohol mixed with EDs (AmEDs) is a particularly alarming combination, given the evidence that consistently associate these drinks with increased risk behaviours and greater alcohol consumption. Caffeine and taurine are commonly found in EDs. In contrast to caffeine, the studies on taurine psychoactive properties and how this amino acid influences ethanol intake alone or in combination with caffeine are not so numerous. OBJECTIVES We summarised relevant and available data on the studies focusing on taurine as a psychoactive agent and its influence on ethanol (EtOH)-induced behaviours. Given the increased risk that represents mixing alcohol with energy drinks, we put emphasis on the research exploring the impact of these combinations on motivated behaviour towards EtOH consumption. RESULTS The research on taurine properties on motivated behaviour towards EtOH consumption is limited, and mostly all done in combination with caffeine or other molecules. This makes it difficult to elucidate the effect of this amino acid when combined with alcohol. CONCLUSIONS Incomplete understanding of the properties and effects of AmEDs is unavoidable until more studies are performed on the influence of taurine on motivation to consume alcohol. Taurine should be further explored, particularly in regard to its potential beneficial applications, motivational properties and synergies with other psychoactive ingredients (i.e. caffeine).
Collapse
Affiliation(s)
- E Tarragon
- Department of Psychobiology and Methodology on Behavioral Sciences, School of Psychology, Complutense University of Madrid, Campus de Somosaguas, Madrid, Spain.
- Universidad Internacional de La Rioja, Faculty of Health Sciences, Avenida de la Paz, 137, 26006, Logroño, La Rioja, Spain.
| | - J Calleja-Conde
- Department of Psychobiology and Methodology on Behavioral Sciences, School of Psychology, Complutense University of Madrid, Campus de Somosaguas, Madrid, Spain
| | - E Giné
- Department of Cellular Biology, School of Medicine, Complutense University of Madrid, Madrid, Spain
| | - L Segovia-Rodríguez
- Department of Psychobiology and Methodology on Behavioral Sciences, School of Psychology, Complutense University of Madrid, Campus de Somosaguas, Madrid, Spain
| | - P Durán-González
- Department of Psychobiology and Methodology on Behavioral Sciences, School of Psychology, Complutense University of Madrid, Campus de Somosaguas, Madrid, Spain
| | - V Echeverry-Alzate
- Department of Psychobiology and Methodology on Behavioral Sciences, School of Psychology, Complutense University of Madrid, Campus de Somosaguas, Madrid, Spain
- Unidad Gestión Clínica de Salud Mental, Instituto de Investigación Biomédica de Málaga (IBIMA), Hospital Regional Universitario de Málaga, Universidad de Málaga, Málaga, Spain
| |
Collapse
|
6
|
Rivas-Delgado A, Nadeu F, Enjuanes A, Magnano L, Castrejón de Anta N, Mozas P, Baumann T, Delgado J, Balagué O, Villamor N, Campo E, Giné E, López-Guillermo A. MUTATIONAL LANDSCAPE OF DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) AT DIAGNOSIS AND AT PROGRESSION ASSESSED BY CIRCULATING TUMOR DNA ANALYSIS. Hematol Oncol 2019. [DOI: 10.1002/hon.1_2630] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Affiliation(s)
- A. Rivas-Delgado
- Hematology Department; Hospital Clínic de Barcelona; Barcelona Spain
| | - F. Nadeu
- Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS); Hospital Clínic; Barcelona Spain
| | - A. Enjuanes
- Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS); Hospital Clínic; Barcelona Spain
| | - L. Magnano
- Hematopathology Unit; Department of Pathology, Hospital Clínic de Barcelona; Barcelona Spain
| | | | - P. Mozas
- Hematology Department; Hospital Clínic de Barcelona; Barcelona Spain
| | - T. Baumann
- Hematology Department; Hospital Clínic de Barcelona; Barcelona Spain
| | - J. Delgado
- Hematology Department; Hospital Clínic de Barcelona; Barcelona Spain
| | - O. Balagué
- Department of Pathology; Hospital Clínic de Barcelona; Barcelona Spain
| | - N. Villamor
- Hematopathology Unit; Department of Pathology, Hospital Clínic de Barcelona; Barcelona Spain
| | - E. Campo
- Department of Pathology; Hospital Clínic de Barcelona; Barcelona Spain
| | - E. Giné
- Hematology Department; Hospital Clínic de Barcelona; Barcelona Spain
| | | |
Collapse
|
7
|
Rivas-Delgado A, Nadeu F, Enjuanes A, Magnano L, Mozas P, Osuna M, Martín S, Baumann T, Castrejón de Anta N, Balagué O, Delgado J, Villamor N, Campo E, Giné E, López-Guillermo A. GENOTYPING PRIMARY MEDIASTINAL B-CELL LYMPHOMA (PMBCL) BY MEANS OF CIRCULATING TUMOR DNA ANALYSIS. Hematol Oncol 2019. [DOI: 10.1002/hon.9_2631] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Affiliation(s)
- A. Rivas-Delgado
- Hematology Department; Hospital Clínic de Barcelona; Barcelona Spain
| | - F. Nadeu
- Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS); Hospital Clínic; Barcelona Spain
| | - A. Enjuanes
- Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS); Hospital Clínic; Barcelona Spain
| | - L. Magnano
- Hematopathology Unit; Department of Pathology, Hospital Clínic de Barcelona; Barcelona Spain
| | - P. Mozas
- Hematology Department; Hospital Clínic de Barcelona; Barcelona Spain
| | - M. Osuna
- Hematopathology Unit; Department of Pathology, Hospital Clínic de Barcelona; Barcelona Spain
| | - S. Martín
- Hematopathology Unit; Department of Pathology, Hospital Clínic de Barcelona; Barcelona Spain
| | - T. Baumann
- Hematology Department; Hospital Clínic de Barcelona; Barcelona Spain
| | | | - O. Balagué
- Department of Pathology; Hospital Clínic de Barcelona; Barcelona Spain
| | - J. Delgado
- Hematology Department; Hospital Clínic de Barcelona; Barcelona Spain
| | - N. Villamor
- Hematopathology Unit; Department of Pathology, Hospital Clínic de Barcelona; Barcelona Spain
| | - E. Campo
- Department of Pathology; Hospital Clínic de Barcelona; Barcelona Spain
| | - E. Giné
- Hematology Department; Hospital Clínic de Barcelona; Barcelona Spain
| | | |
Collapse
|
8
|
Mozas P, Magnano L, Rivas-Delgado A, Rivero A, Nadeu F, Veloza L, González-Farré B, Baumann T, Balagué O, Giné E, Delgado J, Villamor N, Campo E, López-Guillermo A. PATTERNS OF CHANGE IN TREATMENT, SURVIVAL, HISTOLOGICAL TRANSFORMATION, AND SECONDARY MALIGNANCIES OF FOLLICULAR LYMPHOMA OVER THE LAST 4 DECADES: A SINGLE CENTER EXPERIENCE. Hematol Oncol 2019. [DOI: 10.1002/hon.66_2631] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Affiliation(s)
- P. Mozas
- Hematology; Hospital Clínic de Barcelona; Barcelona Spain
| | - L. Magnano
- Hematopathology Unit; Pathology Department, Hospital Clínic de Barcelona; Barcelona Spain
| | | | - A. Rivero
- Hematology; Hospital Clínic de Barcelona; Barcelona Spain
| | - F. Nadeu
- Lymphoid Malignancies; Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS); Barcelona Spain
| | - L. Veloza
- Pathology; Hospital Clínic de Barcelona; Barcelona Spain
| | | | - T. Baumann
- Hematology; Hospital Clínic de Barcelona; Barcelona Spain
| | - O. Balagué
- Pathology; Hospital Clínic de Barcelona; Barcelona Spain
| | - E. Giné
- Hematology; Hospital Clínic de Barcelona; Barcelona Spain
| | - J. Delgado
- Hematology; Hospital Clínic de Barcelona; Barcelona Spain
| | - N. Villamor
- Hematopathology Unit; Pathology Department, Hospital Clínic de Barcelona; Barcelona Spain
| | - E. Campo
- Pathology; Hospital Clínic de Barcelona; Barcelona Spain
| | | |
Collapse
|
9
|
Echeverry-Alzate V, Bühler KM, Calleja-Conde J, Huertas E, Maldonado R, Rodríguez de Fonseca F, Santiago C, Gómez-Gallego F, Santos A, Giné E, López-Moreno JA. Adult-onset hypothyroidism increases ethanol consumption. Psychopharmacology (Berl) 2019; 236:1187-1197. [PMID: 30470859 DOI: 10.1007/s00213-018-5123-1] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/06/2018] [Accepted: 11/14/2018] [Indexed: 12/29/2022]
Abstract
RATIONALE Only in Europe it can be estimated that more than 20 million of people would be affected by hypothyroidism in some moment of their life. Given that ethanol consumption is so frequent, it would be reasonable to ask what the consequences of ethanol consumption in those individuals affected by hypothyroidism are. OBJECTIVES To study the interaction between hypothyroidism and ethanol consumption. METHODS We study ethanol consumption in a rat model of methyl-mercaptoimidazole-induced-adult-onset hypothyroidism and thyroid T4/T3 hormone supplementation. Also, we studied the effects of ethanol on motor activity, memory, and anxiety. RESULTS We found that hypothyroidism increased the voluntary ethanol consumption and that this was enhanced by thyroid hormone supplementation. Hypothyroidism was associated with motor hyperactivity which was prevented either by T4/T3 supplementation or ethanol. The relationship between hypothyroidism, ethanol, and anxiety was more complex. In an anxiogenic context, hypothyroidism and T4/T3 supplementation would increase immobility, an anxiety-like behavior, while in a less anxiogenic context would decrease rearing, a behavior related to anxiety. Regarding memory, acute ethanol administration did not alter episodic-like memory in hypothyroid rats. Gene expression of enzymes involved in the metabolism of ethanol, i.e., Adh1 and Aldh2, were altered by hypothyroidism and T4/T3 supplementation. CONCLUSIONS Our results suggest that hypothyroid patients would need personalized attention in terms of ethanol consumption. In addition, they point that it would be useful to embrace the thyroid axis in the study of ethanol addiction, including as a possible therapeutic target for the treatment of alcoholism and its comorbid disorders.
Collapse
Affiliation(s)
- V Echeverry-Alzate
- Department of Psychobiology & Behavioral Sciences Methods, School of Psychology, Campus de Somosaguas, Complutense University of Madrid, 28223, Madrid, Spain
| | - K M Bühler
- Department of Psychobiology & Behavioral Sciences Methods, School of Psychology, Campus de Somosaguas, Complutense University of Madrid, 28223, Madrid, Spain
| | - J Calleja-Conde
- Department of Psychobiology & Behavioral Sciences Methods, School of Psychology, Campus de Somosaguas, Complutense University of Madrid, 28223, Madrid, Spain
| | - E Huertas
- Department of Experimental Psychology, Cognitive Processes & Speech Therapy, School of Psychology, Complutense University of Madrid, 28223, Madrid, Spain
| | - R Maldonado
- Laboratori de Neurofarmacologia, Departament de Ciències Experimentals i de la Salut, Universitat Pompeu Fabra, 08003, Barcelona, Spain
| | - F Rodríguez de Fonseca
- Fundación IMABIS, Laboratorio de Medicina Regenerativa, Hospital Regional Universitario Carlos Haya, 29010, Málaga, Spain
| | - C Santiago
- Department of Basic Biomedical Science, Faculty of Biomedical and Health Sciences, Universidad Europea de Madrid, Villaviciosa de Odón, 28670, Madrid, Spain
| | - F Gómez-Gallego
- Facultad de Ciencias de la Salud, Universidad Internacional de la Rioja (UNIR), La Rioja, Spain
| | - A Santos
- Department of Biochemistry & Molecular Biology, Faculty of Medicine, Complutense University of Madrid, 28040, Madrid, Spain
| | - E Giné
- Department of Cellular Biology, School of Medicine, Complutense University of Madrid, 28040, Madrid, Spain
| | - J A López-Moreno
- Department of Psychobiology & Behavioral Sciences Methods, School of Psychology, Campus de Somosaguas, Complutense University of Madrid, 28223, Madrid, Spain.
| |
Collapse
|
10
|
Bobillo S, Abrisqueta P, Sánchez-González B, Giné E, Romero S, Alcoceba M, González-Barca E, González de Villambrosía S, Sancho JM, Gómez P, Bento L, Montoro J, Montes S, López A, Bosch F. Posttransplant monomorphic Burkitt’s lymphoma: clinical characteristics and outcome of a multicenter series. Ann Hematol 2018; 97:2417-2424. [DOI: 10.1007/s00277-018-3473-8] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/17/2018] [Accepted: 08/06/2018] [Indexed: 10/28/2022]
|
11
|
Magnano L, Balagué O, Dlouhy I, Rovira J, Karube K, Pinyol M, Rivas-Delgado A, Costa D, Martínez-Trillos A, González-Farre B, Martínez-Pozo A, Giné E, Colomer D, Delgado J, Villamor N, Campo E, López-Guillermo A. Clinicobiological features and prognostic impact of diffuse large B-cell lymphoma component in the outcome of patients with previously untreated follicular lymphoma. Ann Oncol 2017; 28:2799-2805. [PMID: 29045517 DOI: 10.1093/annonc/mdx407] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 08/08/2023] Open
Abstract
BACKGROUND The co-existence at diagnosis of follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL) components (FL/DLBCL) has been considered a transformed lymphoma and accordingly treated although clinicobiological information on these patients is scarce. The aim of this study was to analyze the initial features and outcome of FL/DLBCL patients in the rituximab era. PATIENTS AND METHODS All patients consecutively diagnosed at a single institution with FL/DLBCL (n = 40), as well as those with pure FL (n = 328) or de novo DLBCL (n = 510) as controls. RESULTS The proportion of the DLBCL component was highly variable (median 50%). In 29 FL/DLBCL cases analyzed, the cell of origin was GCB in 86%, ABC in 10% and unclassifiable in 4%. NOTCH1-2 was mutated in 10% of these cases. The proportion of DLBCL component did not impact on overall survival (OS). Regarding initial characteristics, patients with FL/DLBCL were closer to FL in terms of primary nodal origin, good performance status and advanced stage, whereas the other features were intermediate between FL and DLBCL. FL/DLBCL patients were treated as DLBCL with no further intensification. Complete response and primary refractory rates were 65% and 20%, respectively, with these figures being similar to DLBCL and worse than FL. Progression-free survival and OS were intermediate between FL and DLBCL (5-year OS: 85%, 73% and 63% for FL, FL/DLBCL and DLBCL, respectively). FL/DLBCL histology did not reach independent prognostic value for OS in the multivariate analyses. CONCLUSIONS The outcome of FL/DLBCL patients is not worse than that of de novo DLBCL. These cases should be treated with immunochemotherapy as DLBCL, but intensification with ASCT may not be necessary. The biological insights of FL/DLBCL warrants further genetic and molecular studies.
Collapse
MESH Headings
- Aged
- Antineoplastic Combined Chemotherapy Protocols/therapeutic use
- Case-Control Studies
- Female
- Follow-Up Studies
- Humans
- Lymphoma, Follicular/complications
- Lymphoma, Follicular/drug therapy
- Lymphoma, Follicular/mortality
- Lymphoma, Follicular/pathology
- Lymphoma, Large B-Cell, Diffuse/complications
- Lymphoma, Large B-Cell, Diffuse/drug therapy
- Lymphoma, Large B-Cell, Diffuse/mortality
- Lymphoma, Large B-Cell, Diffuse/pathology
- Male
- Neoplasm Recurrence, Local/complications
- Neoplasm Recurrence, Local/drug therapy
- Neoplasm Recurrence, Local/mortality
- Neoplasm Recurrence, Local/pathology
- Prognosis
- Survival Rate
Collapse
Affiliation(s)
- L Magnano
- Department of Hematology, Hospital Clínic, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona;; Hematopathology Unit, Department of Pathology, Hospital Clínic, IDIBAPS, University of Barcelona, Barcelona;; CIBERONC, Barcelona
| | - O Balagué
- CIBERONC, Barcelona;; Department of Pathology, Hospital Clínic, IDIBAPS, University of Barcelona, Barcelona, Spain
| | - I Dlouhy
- Department of Hematology, Hospital Clínic, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona;; CIBERONC, Barcelona
| | - J Rovira
- Department of Hematology, Hospital Clínic, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona;; CIBERONC, Barcelona
| | - K Karube
- Department of Pathology and Cell Biology, Graduate School of Medicine, University of the Ryukyus;; Faculty of Medicine, University of the Ryukyus, Japan
| | - M Pinyol
- CIBERONC, Barcelona;; Genomics Unit, IDIBAPS, Barcelona, Spain
| | - A Rivas-Delgado
- Department of Hematology, Hospital Clínic, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona;; CIBERONC, Barcelona
| | - D Costa
- Hematopathology Unit, Department of Pathology, Hospital Clínic, IDIBAPS, University of Barcelona, Barcelona;; CIBERONC, Barcelona
| | - A Martínez-Trillos
- Department of Hematology, Hospital Clínic, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona;; CIBERONC, Barcelona
| | - B González-Farre
- CIBERONC, Barcelona;; Department of Pathology, Hospital Clínic, IDIBAPS, University of Barcelona, Barcelona, Spain
| | - A Martínez-Pozo
- CIBERONC, Barcelona;; Department of Pathology, Hospital Clínic, IDIBAPS, University of Barcelona, Barcelona, Spain
| | - E Giné
- Department of Hematology, Hospital Clínic, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona;; CIBERONC, Barcelona
| | - D Colomer
- Hematopathology Unit, Department of Pathology, Hospital Clínic, IDIBAPS, University of Barcelona, Barcelona;; CIBERONC, Barcelona
| | - J Delgado
- Department of Hematology, Hospital Clínic, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona;; CIBERONC, Barcelona
| | - N Villamor
- Hematopathology Unit, Department of Pathology, Hospital Clínic, IDIBAPS, University of Barcelona, Barcelona;; CIBERONC, Barcelona
| | - E Campo
- Hematopathology Unit, Department of Pathology, Hospital Clínic, IDIBAPS, University of Barcelona, Barcelona;; CIBERONC, Barcelona
| | - A López-Guillermo
- Department of Hematology, Hospital Clínic, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona;; CIBERONC, Barcelona;.
| |
Collapse
|
12
|
Echeverry-Alzate V, Rincón-Pérez I, Calleja-Conde J, Bühler K, Giné E, Hinojosa J, Albert J, López-Moreno J. S03-1INTERACTIONS BETWEEN MICROBIOTA AND ALCOHOL-RELATED BEHAVIORS. Alcohol Alcohol 2017. [DOI: 10.1093/alcalc/agx075.08] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
13
|
Pérez-Galán P, Vidal-Crespo A, Matas-Céspedes A, Rodriguez V, Rossi C, Roué G, López-Guillermo A, Giné E, Campo E, Colomer D, Wiestner A, Bezombes C, Balasubramanian S, Chiu C, Doshi P. ANTI-TUMOR ACTIVITY OF DARATUMUMAB, A NOVEL HUMAN ANTI CD38 MONOCLONAL ANTIBODY, IN IN VITRO
AND IN VIVO
MODELS OF B-CELL NON-HODGKIN LYMPHOMA. Hematol Oncol 2017. [DOI: 10.1002/hon.2437_29] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Affiliation(s)
| | | | | | | | - C. Rossi
- Hematology-Oncology; Centre de Recherche en Cancérologie de Toulouse (CRCT); Toulouse France
| | - G. Roué
- Hemato-Oncology; IDIBAPS; Barcelona Spain
| | | | - E. Giné
- Hematology; Hospital Clínic-IDIBAPS; Barcelona Spain
| | - E. Campo
- Hematophathology; Hospital Clínic-IDIBAPS; Barcelona Spain
| | - D. Colomer
- Hematophathology; Hospital Clínic-IDIBAPS; Barcelona Spain
| | - A. Wiestner
- Hematology Branch; National Heart, Lung, and Blood Institute, National Institutes of Health; Bethesda Maryland USA
| | - C. Bezombes
- Hematology-Oncology; Centre de Recherche en Cancérologie de Toulouse (CRCT); Toulouse France
| | | | - C. Chiu
- Oncology; Janssen R&D, Spring House; Pennsylvania USA
| | - P. Doshi
- Oncology; Janssen R&D, Spring House; Pennsylvania USA
| |
Collapse
|
14
|
Bobillo S, Abrisqueta P, Sánchez-González B, Giné E, Romero S, Alcoceba M, González-Barca E, González de Villambrosía S, Sancho J, Castellví J, López A, Bosch F. Post-transplant monomorphic Burkitt's lymphoma: Clinical characteristics and outcome of a multicenter series. Hematol Oncol 2017. [DOI: 10.1002/hon.2439_100] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Affiliation(s)
- S. Bobillo
- Department of Hematology; Vall d'Hebron University Hospital; Barcelona Spain
| | - P. Abrisqueta
- Department of Hematology; Vall d'Hebron University Hospital; Barcelona Spain
| | | | - E. Giné
- Department of Hematology; Hospital Clinic; Barcelona Spain
| | - S. Romero
- Department of Hematology; Hospital La Fe; València Spain
| | - M. Alcoceba
- Department of Hematology; Hospital Universitario de Salamanca; Salamanca Spain
| | - E. González-Barca
- Department of Hematology, Institut Català d'Oncologia; Hospital Duran y Reynals, L'Hospitalet de Llobregat; Spain
| | | | - J.M. Sancho
- Department of Hematology; ICO-IJC-University Hospital Germans Trias y Pujol; Badalona Spain
| | - J. Castellví
- Department of Pathology; Vall d'Hebron University Hospital; Barcelona Spain
| | - A. López
- Department of Hematology; Vall d'Hebron University Hospital; Barcelona Spain
| | - F. Bosch
- Department of Hematology; Vall d'Hebron University Hospital; Barcelona Spain
| |
Collapse
|
15
|
Esteban D, Tovar N, Jiménez R, Santacruz R, Baumann T, Pastor MC, de la Riva A, Carrera E, Chaves S, Royo C, Navarro A, Rodríguez S, Ayuso C, Riu G, Creus N, Gómez B, Giné E, López-Guillermo A, Delgado J. Patients with relapsed/refractory chronic lymphocytic leukaemia may benefit from inclusion in clinical trials irrespective of the therapy received: a case-control retrospective analsysis. Blood Cancer J 2015; 5:e356. [PMID: 26430727 PMCID: PMC4635190 DOI: 10.1038/bcj.2015.78] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022] Open
Affiliation(s)
- D Esteban
- Department of Haematology, Hospital Clínic, IDIBAPS, Barcelona, Spain
| | - N Tovar
- Department of Haematology, Hospital Clínic, IDIBAPS, Barcelona, Spain
| | - R Jiménez
- Department of Haematology, Hospital Clínic, IDIBAPS, Barcelona, Spain
| | - R Santacruz
- Department of Haematology, Hospital Clínic, IDIBAPS, Barcelona, Spain
| | - T Baumann
- Department of Haematology, Hospital Clínic, IDIBAPS, Barcelona, Spain
| | - M C Pastor
- Department of Haematology, Hospital Clínic, IDIBAPS, Barcelona, Spain
| | - A de la Riva
- Department of Haematology, Hospital Clínic, IDIBAPS, Barcelona, Spain
| | - E Carrera
- Department of Haematology, Hospital Clínic, IDIBAPS, Barcelona, Spain
| | - S Chaves
- Department of Haematology, Hospital Clínic, IDIBAPS, Barcelona, Spain
| | - C Royo
- Haematopathology Unit, Hospital Clínic, IDIBAPS, Barcelona, Spain
| | - A Navarro
- Haematopathology Unit, Hospital Clínic, IDIBAPS, Barcelona, Spain
| | - S Rodríguez
- Department of Radiology, Hospital Clínic, Barcelona, Spain
| | - C Ayuso
- Department of Radiology, Hospital Clínic, Barcelona, Spain
| | - G Riu
- Department of Pharmacy, Hospital Clínic, Barcelona, Spain
| | - N Creus
- Department of Pharmacy, Hospital Clínic, Barcelona, Spain
| | - B Gómez
- Department of Pharmacy, Hospital Clínic, Barcelona, Spain
| | - E Giné
- Department of Haematology, Hospital Clínic, IDIBAPS, Barcelona, Spain
| | - A López-Guillermo
- Department of Haematology, Hospital Clínic, IDIBAPS, Barcelona, Spain
| | - J Delgado
- Department of Haematology, Hospital Clínic, IDIBAPS, Barcelona, Spain
| |
Collapse
|
16
|
Echeverry-Alzate V, Marcos M, Calleja-Conde J, Bühler KM, Costa-Alba P, Bernardo E, Laso FJ, Rodríguez de Fonseca F, Nadal R, Viveros MP, Maldonado R, Giné E, López-Moreno JA. P-34EFFECTS OF ALCOHOL BINGES ON HISTONE DEACETYLASES GENE EXPRESSION IN RATS AND HUMANS. Alcohol Alcohol 2015. [DOI: 10.1093/alcalc/agv080.34] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
17
|
Calleja-Cond J, Echeverry-Alzate V, Bühler KM, Giné E, Gual A, López-Moreno JA. P-80NALMEFENE IS EFFECTIVE REDUCING OPERANT ALCOHOL SELF-ADMINISTRATION EVEN WHEN THERE IS A CO-ADMINISTRATION OF COCAINE. Alcohol Alcohol 2015. [DOI: 10.1093/alcalc/agv080.80] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
18
|
Echeverry-Alzate V, Giné E, Bühler KM, Calleja-Conde J, Olmos P, Gorriti MA, Nadal R, Rodríguez de Fonseca F, López-Moreno JA. Effects of topiramate on ethanol-cocaine interactions and DNA methyltransferase gene expression in the rat prefrontal cortex. Br J Pharmacol 2015; 171:3023-36. [PMID: 24527678 DOI: 10.1111/bph.12636] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/18/2013] [Revised: 01/27/2014] [Accepted: 02/01/2014] [Indexed: 01/29/2023] Open
Abstract
BACKGROUND AND PURPOSE Recent and ongoing clinical studies have indicated that topiramate (Topamax®) could be effective in treating ethanol or cocaine abuse. However, the effects of topiramate on the co-administration of ethanol and cocaine remain largely unknown. EXPERIMENTAL APPROACH We studied the effects of topiramate, in Wistar rats, on operant ethanol self-administration with the co-administration of cocaine (i.p.). The psychomotor effects of topiramate were examined before ethanol self-administration and cocaine exposure. Blood samples were collected to analyse ethanol and cocaine metabolism (blood ethanol levels and benzoylecgonine). Quantitative real-time PCR was used to characterize the gene expression in the prefrontal cortex. KEY RESULTS Topiramate prevented the cocaine-induced increased response to ethanol in a dose-dependent manner without causing any motor impairment by itself. This effect was observed when topiramate was administered before ethanol access, but not when topiramate was administered before the cocaine injection. Topiramate did not block cocaine-induced psychomotor stimulation. Topiramate reduced blood ethanol levels but did not affect cocaine metabolism. Ethanol increased the gene expression of DNA methyltransferases (Dnmt1 and Dnmt3a), the corepressor Dnmt1-associated protein 1 (Dmap1), and the RNA methyltransferase Trdmt1. These effects were prevented by topiramate or cocaine. Gene expression of histone deacetylase-2 and glutamate receptor kainate-1 were only increased by cocaine treatment. Topiramate and cocaine co-administration caused an up-regulation of dopamine (Drd1, Th) and opioid (Oprm1) receptor genes. Topiramate showed a tendency to alter episodic-like memory. CONCLUSIONS AND IMPLICATIONS Topiramate is an effective inhibitor of the cocaine-induced increase in operant ethanol self-administration.
Collapse
Affiliation(s)
- V Echeverry-Alzate
- Department of Psychobiology, School of Psychology, Campus de Somosaguas, Complutense University of Madrid, Madrid, Spain
| | | | | | | | | | | | | | | | | |
Collapse
|
19
|
Fernández de Larrea C, Jiménez R, Rosiñol L, Giné E, Tovar N, Cibeira MT, Fernández-Avilés F, Martínez C, Rovira M, Bladé J. Pattern of relapse and progression after autologous SCT as upfront treatment for multiple myeloma. Bone Marrow Transplant 2013; 49:223-7. [PMID: 24076551 DOI: 10.1038/bmt.2013.150] [Citation(s) in RCA: 24] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/12/2013] [Revised: 07/11/2013] [Accepted: 08/13/2013] [Indexed: 12/11/2022]
Abstract
The achievement of CR is the crucial step for a prolonged PFS and OS after an autologous SCT in multiple myeloma (MM). Unfortunately, even with the use of new regimens and the current high CR rates, most, if not all, patients will ultimately relapse or progress. We analyzed the type of relapse or progression (asymptomatic vs symptomatic), clinical features including the presence of extramedullary involvement and time to next treatment in 211 patients who underwent melphalan-based autologous SCT over an 18-year period at our institution. After autologous SCT, serological or asymptomatic relapse/progression was observed in about one half of the patients. The treatment-free interval was significantly longer in patients relapsing from CR than in those progressing from PR (P=0.017). Patients with serological relapse/progression had a significantly longer OS than those relapsing from symptomatic disease (P=0.002). The relapse pattern was similar to the initial clinical presentation. Survival after relapse/progression was shorter in those patients with a 24-h urine M-protein excretion of at least 200 mg (P=0.048). Extramedullary involvement was frequent (24%), being the highest risk in patients with extramedullary involvement at diagnosis (P=0.001).
Collapse
Affiliation(s)
- C Fernández de Larrea
- Amyloidosis and Myeloma Unit, Department of Hematology, Servei d'Hematologia, Hospital Clínic de Barcelona, Institut d'Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), University of Barcelona, Barcelona, Spain
| | - R Jiménez
- Amyloidosis and Myeloma Unit, Department of Hematology, Servei d'Hematologia, Hospital Clínic de Barcelona, Institut d'Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), University of Barcelona, Barcelona, Spain
| | - L Rosiñol
- Amyloidosis and Myeloma Unit, Department of Hematology, Servei d'Hematologia, Hospital Clínic de Barcelona, Institut d'Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), University of Barcelona, Barcelona, Spain
| | - E Giné
- Amyloidosis and Myeloma Unit, Department of Hematology, Servei d'Hematologia, Hospital Clínic de Barcelona, Institut d'Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), University of Barcelona, Barcelona, Spain
| | - N Tovar
- Amyloidosis and Myeloma Unit, Department of Hematology, Servei d'Hematologia, Hospital Clínic de Barcelona, Institut d'Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), University of Barcelona, Barcelona, Spain
| | - M T Cibeira
- Amyloidosis and Myeloma Unit, Department of Hematology, Servei d'Hematologia, Hospital Clínic de Barcelona, Institut d'Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), University of Barcelona, Barcelona, Spain
| | - F Fernández-Avilés
- Amyloidosis and Myeloma Unit, Department of Hematology, Servei d'Hematologia, Hospital Clínic de Barcelona, Institut d'Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), University of Barcelona, Barcelona, Spain
| | - C Martínez
- Amyloidosis and Myeloma Unit, Department of Hematology, Servei d'Hematologia, Hospital Clínic de Barcelona, Institut d'Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), University of Barcelona, Barcelona, Spain
| | - M Rovira
- Amyloidosis and Myeloma Unit, Department of Hematology, Servei d'Hematologia, Hospital Clínic de Barcelona, Institut d'Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), University of Barcelona, Barcelona, Spain
| | - J Bladé
- Amyloidosis and Myeloma Unit, Department of Hematology, Servei d'Hematologia, Hospital Clínic de Barcelona, Institut d'Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), University of Barcelona, Barcelona, Spain
| |
Collapse
|
20
|
Cheah C, George A, Giné E, Chiappella A, Kluin-Nelemans H, Jurczak W, Krawczyk K, Mocikova H, Klener P, Salek D, Walewski J, Szymczyk M, Smolej L, Auer R, Ritchie D, Arcaini L, Williams M, Dreyling M, Seymour J. Central nervous system involvement in mantle cell lymphoma: clinical features, prognostic factors and outcomes from the European Mantle Cell Lymphoma Network. Ann Oncol 2013; 24:2119-23. [DOI: 10.1093/annonc/mdt139] [Citation(s) in RCA: 82] [Impact Index Per Article: 7.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
21
|
Gonzalez EA, Mensa A, Villarroel P, Diaz M, Fabregat V, Santiago F, Giné E, Serra-Pages C. Identification of a new HLA-C allele, HLA-C*08:75 in a Caucasian individual. Tissue Antigens 2013; 82:68-69. [PMID: 23745573 DOI: 10.1111/tan.12111] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 02/05/2013] [Accepted: 03/07/2013] [Indexed: 06/02/2023]
Abstract
HLA-C*08:75 differs from C*08:02:01 by a non-synonymous mutation at codon 229 (GAG to AAG) in exon 4.
Collapse
Affiliation(s)
- E A Gonzalez
- Servei d'Immunologia, Hospital Clinic, Barcelona, Spain
| | | | | | | | | | | | | | | |
Collapse
|
22
|
Garrido P, De Blas M, Ronzoni G, Cordero I, Antón M, Giné E, Santos A, Del Arco A, Segovia G, Mora F. Differential effects of environmental enrichment and isolation housing on the hormonal and neurochemical responses to stress in the prefrontal cortex of the adult rat: relationship to working and emotional memories. J Neural Transm (Vienna) 2012; 120:829-43. [DOI: 10.1007/s00702-012-0935-3] [Citation(s) in RCA: 38] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/18/2012] [Accepted: 11/29/2012] [Indexed: 12/17/2022]
|
23
|
Villamor N, Conde L, Martínez-Trillos A, Cazorla M, Navarro A, Beà S, López C, Colomer D, Pinyol M, Aymerich M, Rozman M, Abrisqueta P, Baumann T, Delgado J, Giné E, González-Díaz M, Hernández JM, Colado E, Payer AR, Rayon C, Navarro B, José Terol M, Bosch F, Quesada V, Puente XS, López-Otín C, Jares P, Pereira A, Campo E, López-Guillermo A. NOTCH1 mutations identify a genetic subgroup of chronic lymphocytic leukemia patients with high risk of transformation and poor outcome. Leukemia 2012; 27:1100-6. [DOI: 10.1038/leu.2012.357] [Citation(s) in RCA: 143] [Impact Index Per Article: 11.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022]
|
24
|
Gutiérrez-García G, García-Herrera A, Cardesa T, Martínez A, Villamor N, Ghita G, Martínez-Trillos A, Colomo L, Setoain X, Rodríguez S, Giné E, Campo E, López-Guillermo A. Comparison of four prognostic scores in peripheral T-cell lymphoma. Ann Oncol 2011; 22:397-404. [PMID: 20631009 DOI: 10.1093/annonc/mdq359] [Citation(s) in RCA: 68] [Impact Index Per Article: 5.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022] Open
Affiliation(s)
- G Gutiérrez-García
- Department of Hematology, Institut de Recerca Biome`dica August Pi i Sunyer, Barcelona, Spain
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
25
|
Alén F, Santos A, Moreno-Sanz G, González-Cuevas G, Giné E, Franco-Ruiz L, Navarro M, López-Moreno JA. Cannabinoid-induced increase in relapse-like drinking is prevented by the blockade of the glycine-binding site of N-methyl-D-aspartate receptors. Neuroscience 2008; 158:465-73. [PMID: 18977415 DOI: 10.1016/j.neuroscience.2008.10.002] [Citation(s) in RCA: 26] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/01/2008] [Revised: 09/30/2008] [Accepted: 10/06/2008] [Indexed: 11/30/2022]
Abstract
The endocannabinoid system is a neuromodulatory system which controls the release of multiple neurotransmitters, including glutamate and both, the endocannabinoid and glutamatergic systems, have been implicated in alcohol relapse. Cannabinoid agonists induce an increase in relapse-like drinking whereas glutamate receptor antagonists could prevent it. Here we hypothesize that cannabinoid-induced increases in relapse-like alcohol drinking could be mediated by glutamatergic N-methyl-d-aspartate (NMDA) receptors. To test this hypothesis, Wistar rats with a background of alcohol operant self-administration were treated with the cannabinoid receptor agonist (R)-(+)-[2,3-dihydro-5-methyl-3-(4-morpholinylmethyl), pyrrolo [1,2,3-de]-1,4-benzoxazin-6-yl]-1-naphthalenylmethanone mesylate (WIN 55.212-2, WIN) (2.0 mg/kg) during periods of alcohol deprivation. For five consecutive days, 30 min before the reintroduction of alcohol, rats were injected with the NMDA/glycine receptor antagonist 7-chloro-4-hydroxy-3-(3-phenoxy)phenylquinolin-2-[1H]-one (L-701) (1.25-5.0 mg/kg) and alcohol reinforcement was evaluated. Our results clearly show that L-701 prevented the cannabinoid-induced increase in relapse-like drinking in a dose-dependent manner, whereas L-701 alone, in the absence of WIN treatment, did not significantly alter alcohol intake. The potentiation of relapse-like drinking induced by WIN is not caused by nonspecific anxiogenic effects, since no effect was observed in the elevated-plus maze test. These alcohol-related behaviors are linked to differential changes in CNR1 and NR1 subunit mRNA transcripts. In WIN-treated rats, an increase in CNR1 transcript levels was observed in the hypothalamus and striatum, whereas in the amygdala and anterior cingulate cortex, brain regions involved in emotional processing, a decrease was observed. Interestingly, such changes were blocked after L-701 treatment. Finally, WIN treatment also caused a reduction in NR1 mRNA levels in the amygdala. In conclusion, pharmacological inactivation of the glycine-binding site of NMDA receptors may control cannabinoid-induced relapse-like drinking, which is associated with altered expression of CNR1 and NR1 gene expression as observed after WIN treatment.
Collapse
Affiliation(s)
- F Alén
- Departamento de Psicobiología, Facultad de Psicología, Facultad de Psicología, Campus Somosaguas Universidad Complutense de Madrid, E-28223 Madrid, Spain
| | | | | | | | | | | | | | | |
Collapse
|
26
|
|
27
|
Giné E, Montoto S, Bosch F, Arenillas L, Mercadal S, Villamor N, Martínez A, Colomo L, Campo E, Montserrat E, López-Guillermo A. The Follicular Lymphoma International Prognostic Index (FLIPI) and the histological subtype are the most important factors to predict histological transformation in follicular lymphoma. Ann Oncol 2006; 17:1539-45. [PMID: 16940035 DOI: 10.1093/annonc/mdl162] [Citation(s) in RCA: 94] [Impact Index Per Article: 5.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/01/2023] Open
Abstract
BACKGROUND Histological transformation (HT) is a well-known event in patients with follicular lymphoma (FL) conferring an unfavorable prognosis. The aim of the study was to analyze incidence and risk factors for HT in a large series of FL patients. PATIENTS AND METHODS 276 patients (median age: 54 years; M139/F137) diagnosed with FL (42% grade 1, 51% 2, 7% 3) in a single institution were studied. Initial treatment consisted of combined chemotherapy in most cases. Median survival was 11.3 years. Main clinic and biological variables were assessed for HT and survival. RESULTS 30 of 276 patients (11%) presented HT after a median follow-up of 6.5 years, with a risk of 15% and 22% at 10 and at 15 years, respectively. All HT corresponded to diffuse large B-cell lymphoma (DLBCL). Grade 3 histology, nodal areas >4, increased LDH and beta(2)-microglobulin, and high-risk IPI and FLIPI were associated with HT. In multivariate analysis, grade 3 histology and FLIPI retained prognostic significance. Only FLIPI predicted HT in grade 1-2 patients. 28 patients received salvage treatment for HT, with a CR rate of 52%. Median survival from transformation was 1.2 years, with 6/13 CR patients being alive >5 years after HT. CONCLUSION FLIPI and histology were the most important variables predicting HT. Upon HT, only patients achieving CR reached prolonged survival, thus emphasizing the need for effective therapies once this event occurs.
Collapse
Affiliation(s)
- E Giné
- Institute of Hematology and Oncology, Department of Hematology and Hematopathology Unit, Hospital Clínic, IDIBAPS, Barcelona, Spain
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
28
|
Nadal E, Giné E, Bladé J, Esteve J, Rosiñol L, Fernández-Avilés F, Marin P, Martinez C, Rovira M, Urbano-Ispizua A, Carreras E, Montserrat E. High-dose therapy/autologous stem cell transplantation in patients with chemosensitive multiple myeloma: predictors of complete remission. Bone Marrow Transplant 2004; 33:61-4. [PMID: 14704657 DOI: 10.1038/sj.bmt.1704313] [Citation(s) in RCA: 42] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
High-dose therapy (HDT) followed by autologous stem cell support is widely used as intensification treatment in patients with multiple myeloma (MM) responsive to the initial chemotherapy. However, there is growing evidence that only the subset of patients who achieve complete remission (CR) actually benefit from this approach. The aim of this study was to identify pretransplant predictors of CR in responding myeloma patients intensified with HDT. A total of 59 patients with chemosensitive disease received myeloablative therapy. The intensification regimen consisted of MEL-200 (23), MEL-140/TBI 12 Gy (21) or busulfan-based regimens (15). Serum and urine negative immunofixation were required for CR. After HDT, the CR rate increased from 8 to 37%. For the overall series, the median event-free survival (EFS) and overall survival (OS) from the initiation of therapy were 41 and 68 months, respectively. Patients who achieved CR had an EFS (median 47 vs 36 months; P=0.023) as well as an OS (median not reached vs 60 months; P=0.006) significantly longer than those attaining a lower degree of response. Finally, the pretransplant features significantly associated to CR were a low M-protein size (serum </=10 g/l and urine <0.5 g/24 h) (P=0.0003) and a proportion of bone marrow plasma cells of </=5% (P=0.02).
Collapse
Affiliation(s)
- E Nadal
- Hematology Department, BMT Section, Institute of Hemato-Oncology, Hospital Clínic, IDIBAPS, Barcelona, Spain
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
29
|
Rosiñol L, Bladé J, Esteve J, Aymerich M, Rozman M, Montoto S, Giné E, Nadal E, Filella X, Queralt R, Carrió A, Montserrat E. Smoldering multiple myeloma: natural history and recognition of an evolving type. Br J Haematol 2003; 123:631-6. [PMID: 14616966 DOI: 10.1046/j.1365-2141.2003.04654.x] [Citation(s) in RCA: 101] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
Patients with smoldering multiple myeloma (SMM) meet the diagnostic criteria of multiple myeloma (MM) but are asymptomatic. Between January 1978 and July 2001, 53 patients (median age 63 years) were diagnosed with SMM. The median serum M-protein and proportion of bone marrow plasma cells were 36 g/l and 27% respectively. Two subsets of SMM were identified: (i) evolving SMM (n = 22), characterized by a progressive increase in serum M-protein, a previously recognized monoclonal gammopathy of undetermined significance (MGUS) and a significant higher proportion of IgA type and (ii) non-evolving SMM (n = 26) with stable M-protein that abruptly increases when symptomatic MM develops. Thirty-four patients developed symptomatic MM. The median time to progression in the overall series was 3.2 years and the only feature associated with a shorter time to progression was the evolving versus non-evolving type (1.3 vs. 3.9 years respectively, P = 0.007). The pattern of progression consisted of anaemia, lytic bone lesions or both, without renal failure, hypercalcaemia or extramedullary plasmacytomas. Fifty-seven per cent of patients that required chemotherapy showed no or minimal response. The median survival from diagnosis and from progression was 8.2 and 3.5 years respectively.
Collapse
Affiliation(s)
- L Rosiñol
- Hematology Department, Institut Clínic de Malalties Hemato-Oncològiques, Hospital Clínic, University of Barcelona, Barcelona, Spain
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
30
|
Giné E, Rovira M, Real I, Burrel M, Montaña J, Carreras E, Montserrat E. Successful treatment of severe hemorrhagic cystitis after hemopoietic cell transplantation by selective embolization of the vesical arteries. Bone Marrow Transplant 2003; 31:923-5. [PMID: 12748670 DOI: 10.1038/sj.bmt.1703954] [Citation(s) in RCA: 40] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
Hemorrhagic cystitis (HC) is a common and sometimes life-threatening complication of hemopoietic cell transplantation (HCT) occurring in 7-52% of transplant recipients. In this setting it is usually either related to the use of cyclophosphamide or to a viral infection (BK, JC viruses and adenovirus type 11). Treatment is based on hyperhydration, platelet and blood-cell transfusions, bladder irrigation and pain management. Where these measures have failed to control HC, numerous therapeutic approaches including surgery have been tried with poor success. We report two HCT patients with severe HC successfully treated with selective embolization of the vesical arteries.
Collapse
Affiliation(s)
- E Giné
- BMT Unit, Hematology Department, Institute of Hematology and Oncology, Postgraduate School of Hematology, Spain
| | | | | | | | | | | | | |
Collapse
|
31
|
Montoto S, Rozman M, Rosiñol L, Nadal E, Giné E, Aymerich M, Ferrer A, Esteve J, Bosch F, López-Guillermo A, Bladé J, Montserrat E. Malignant transformation in IgM monoclonal gammopathy of undetermined significance. Semin Oncol 2003; 30:178-81. [PMID: 12720132 DOI: 10.1053/sonc.2003.50067] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Abstract
Monoclonal gammopathy of undetermined significance (MGUS) is a frequent disorder characterized by the presence of a small serum M-protein in individuals with no evidence of multiple myeloma (MM), Waldenstrom's macroglobulinemia (WM), or primary amyloidosis (AL). Although one fourth of these individuals will develop a malignant disease, there are no well-established predictors of outcome, particularly in the IgM type MGUS. Among 434 patients diagnosed with MGUS from 1970 to 2001 with a minimum follow-up of 1 year, 52 (27 men and 25 women; median age, 67 years) of IgM type were identified. After a median follow-up of 5 years, five patients (9.6%) have developed WM. The risk of transformation was 13.3% (95% confidence interval [CI], 0 to 27) and 27.7% (95% CI, 0.3 to 55.1) at 10 and 20 years, respectively. The variables significantly associated with transformation were the proportion of bone marrow plasma cells (BMPC) and the percentage of bone marrow lymphocytes (BML). No significant differences in the risk of transformation were found between IgM MGUS and the remaining MGUS types. Thus, in IgM MGUS the rate of transformation was similar to the risk observed in other MGUS types, the percentage of BMPC and BML being the features significantly associated with evolution into WM.
Collapse
Affiliation(s)
- S Montoto
- Institute of Hematology and Oncology, Postgraduate School of Hematology Farreras-Valentí, Department of Hematology and Hematopathology Unit, IDIBAPS, Hospital Clínic, Barcelona, Spain
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
32
|
Giné E, Bosch F, Villamor N, Rozman M, Colomer D, López-Guillermo A, Campo E, Montserrat E. Simultaneous diagnosis of hairy cell leukemia and chronic lymphocytic leukemia/small lymphocytic lymphoma: a frequent association? Leukemia 2002; 16:1454-9. [PMID: 12145685 DOI: 10.1038/sj.leu.2402553] [Citation(s) in RCA: 27] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/04/2001] [Accepted: 02/27/2002] [Indexed: 11/09/2022]
Abstract
The association of hairy cell leukemia (HCL) with other neoplasms, mainly non-Hodgkin's lymphomas, is well known. However, the simultaneous diagnosis of HCL and chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) is rare, with only few cases of such an association having been reported. We describe three patients with a well-characterized HCL in whom a CLL/SLL population was detected. Of note, these cases represent a significant proportion (11.5%; 95% CI: 0% to 24%) of the total number of HCL cases diagnosed in our institution during the same period of time. All three patients were treated with deoxycoformycin. They achieved a complete response of the HCL, whereas the CLL/SLL population persisted in all cases. The immunoglobulin gene rearrangement analysis, in two informative cases, suggested that the HCL and CLL/SLL populations arose from different B cell clones. This study indicates that the association of HCL and CLL/SLL might be much more frequent than previously recognized. Therefore, a large panel of monoclonal antibodies, including those necessary to detect CLL/SLL, should be employed when studying patients with HCL.
Collapse
MESH Headings
- Antimetabolites, Antineoplastic/therapeutic use
- B-Lymphocytes/pathology
- Cell Lineage
- Cladribine/therapeutic use
- Combined Modality Therapy
- Comorbidity
- Gene Rearrangement, B-Lymphocyte
- Genes, Immunoglobulin
- Hematopoietic Stem Cell Transplantation
- Humans
- Immunophenotyping
- Leukemia, Hairy Cell/diagnosis
- Leukemia, Hairy Cell/drug therapy
- Leukemia, Hairy Cell/epidemiology
- Leukemia, Hairy Cell/therapy
- Leukemia, Lymphocytic, Chronic, B-Cell/diagnosis
- Leukemia, Lymphocytic, Chronic, B-Cell/drug therapy
- Leukemia, Lymphocytic, Chronic, B-Cell/epidemiology
- Leukemia, Lymphocytic, Chronic, B-Cell/therapy
- Male
- Mass Screening
- Middle Aged
- Neoplasms, Multiple Primary/diagnosis
- Neoplasms, Multiple Primary/drug therapy
- Neoplasms, Multiple Primary/epidemiology
- Neoplasms, Multiple Primary/therapy
- Neoplastic Stem Cells/pathology
- Pentostatin/therapeutic use
- Prospective Studies
- Remission Induction
- Salvage Therapy
- Transplantation, Autologous
Collapse
Affiliation(s)
- E Giné
- Institute of Hematology and Oncology, Department of Hematology, Hospital Clínic, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain
| | | | | | | | | | | | | | | |
Collapse
|
33
|
Bustamante J, Lobo MV, Alonso FJ, Mukala NT, Giné E, Solís JM, Tamarit-Rodriguez J, Martín Del Río R. An osmotic-sensitive taurine pool is localized in rat pancreatic islet cells containing glucagon and somatostatin. Am J Physiol Endocrinol Metab 2001; 281:E1275-85. [PMID: 11701444 DOI: 10.1152/ajpendo.2001.281.6.e1275] [Citation(s) in RCA: 31] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
Previous reports have dealt with the hypoglycemic properties of taurine and its effects on insulin secretion by adult and fetal isolated islets. We have studied the presence and cellular distribution of taurine in rat islets, the conditions to evoke its release, and its possible modulatory action on insulin secretion. We localized taurine by techniques of double immunolabeling in most glucagon-positive cells and in some somatostatin-positive cells, whereas insulin-positive cells were not labeled with the taurine antibody. Although high-glucose stimulation did not evoke any taurine release, a hyposmotic solution (17% osmolarity reduction) induced a specific phasic release of taurine and GABA (34 and 52% increase on their basal release rate). On the other hand, taurine (10 mmol/l) application slightly reduced the second phase of insulin secretion induced by glucose stimulation. In conclusion, taurine is highly concentrated in glucagon-containing cells of the islet periphery. It is not liberated by glucose stimulation but is strongly released under hyposmotic conditions. All of these data suggest that taurine plays an osmoregulatory role in alpha-cells.
Collapse
Affiliation(s)
- J Bustamante
- Department of Physiology, Faculty of Medicine, Universidad Complutense, 28040 Madrid, Spain.
| | | | | | | | | | | | | | | |
Collapse
|
34
|
Becker E, Soler RM, Yuste VJ, Giné E, Sanz-Rodríguez C, Egea J, Martín-Zanca D, Comella JX. Development of survival responsiveness to brain-derived neurotrophic factor, neurotrophin 3 and neurotrophin 4/5, but not to nerve growth factor, in cultured motoneurons from chick embryo spinal cord. J Neurosci 1998; 18:7903-11. [PMID: 9742158 PMCID: PMC6793005] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/08/2023] Open
Abstract
During embryonic development, most neuronal populations undergo a process usually referred to as naturally occurring neuronal death. For motoneurons (MTNs) of the lumbar spinal cord of chick embryos, this process takes place in a well defined period of time, between embryonic days 6 and 10 (E6-E10). Neurotrophins (NTs) are the best characterized family of neurotrophic factors and exert their effects through activation of their specific Trk receptors. In vitro and in vivo studies have demonstrated that rodent motoneurons survive in response to BDNF, NT3, and NT4/5. In contrast, the trophic dependencies of chicken motoneurons have been difficult to elucidate, and various apparently conflicting reports have been published. In the present study, we describe how freshly isolated motoneurons from E5.5 chick embryos did not respond to any neurotrophin in vitro. Yet, because motoneurons were maintained alive in culture in the presence of muscle extract, they developed a delayed specific survival response to BDNF, NT3, and NT4/5 that is clearly dose-dependent, reaching saturation at doses of 100 pg/ml. This trophic response correlated with increasing expression of the corresponding functional receptors TrkB and TrkC. Moreover, TrkB receptor is able to become autophosphorylated and to activate classical intracellular signaling pathways such as the extracellular signal-regulated protein kinase when it is stimulated with its cognate ligand BDNF. Therefore, our results reconcile the reported differences between in vivo and in vitro studies on the ability of chicken MTNs to respond to some members of the neurotrophin family of trophic factors.
Collapse
Affiliation(s)
- E Becker
- Instituto de Microbiología Bioquímica, Departamento de Microbiología y Genética, Consejo Superior de Investigaciones Científicas-Universidad de Salamanca, 37007 Salamanca, Spain
| | | | | | | | | | | | | | | |
Collapse
|
35
|
Abstract
Lactate production, glucose utilization, glucose oxidation, and insulin release were studied in islets from rat and ob/ob mice. Lactate was determined with a highly sensitive method, based on esterification, subsequent separation, and quantitation with high-performance liquid chromatography. There was a significant lactate production in the absence of glucose, which increased with glucose concentrations up to 3 mmol/l, reaching its half-maximal rate in the presence of 0.2-1.0 mmol/l glucose in both species. Glucose utilization displayed a wider glucose concentration dependence, with a K0.5 value between 3 and 10 mmol/l glucose. The rates of glucose utilization and lactate production were similar at 3 mmol/l glucose in rat islets and at about 6 mmol/l glucose in ob/ob mice islets. Saturation of lactate production at low glucose concentrations is probably contributing to the observed preferential stimulation of oxidative metabolism at higher concentrations. D-Mannoheptulose caused a marked inhibition of glucose utilization and glucose oxidation at 20 mmol/l glucose in islets from rat or ob/ob mice, as would be expected from a competitive inhibition of glucokinase. By contrast, D-mannoheptulose reduced only marginally the islet metabolism at 3 mmol/l glucose, which is consistent with an effective mannoheptulose-induced inhibition of the glucokinase-dependent, minor part of glucose phosphorylation at this low glucose concentration.
Collapse
Affiliation(s)
- J Tamarit-Rodriguez
- Department of Biochemistry, School of Medicine, Complutense University, Madrid, Spain.
| | | | | | | | | |
Collapse
|
36
|
Bustamante J, Alonso FJ, Lobo MV, Giné E, Tamarit-Rodriguez J, Solís JM, Martín del Río R. Taurine levels and localization in pancreatic islets. Adv Exp Med Biol 1998; 442:65-9. [PMID: 9635015 DOI: 10.1007/978-1-4899-0117-0_8] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
Affiliation(s)
- J Bustamante
- Depto. Fisiología, Facultad de Medicina, Universidad Complutense, Madrid, Spain
| | | | | | | | | | | | | |
Collapse
|
37
|
Abstract
The secretory, metabolic, and signaling aspects of glucose/palmitate interaction on beta-cell function have been studied on rat islets. Palmitate potentiated the glucose-induced insulin response of perifused islets at suprathreshold (>3 mmol/l) sugar concentrations. This potentiating effect could be suppressed by 8-bromo-cGMP, which also blocks palmitate metabolism. Palmitate did not modify glucose utilization, but it slightly reduced glucose oxidation and concomitantly increased lactate production. The very low rate of palmitate oxidation (80-fold lower than that of 20 mmol/l glucose) might explain its lack of effect on glycolysis and hence that the glucose/fatty acid cycle is inoperative in islet cells. However, glucose determines the metabolic fate of exogenous palmitate, which is mainly diverted toward lipid synthesis at high sugar concentrations and might then generate lipid messengers for cell signaling. Palmitate did not increase glucose-induced production of inositol-1,4,5-trisphosphate, but it stimulated the translocation of protein kinase C activity from a cytosolic to a particulate fraction at 20 but not at 3 mmol/l glucose. This increased translocation was partially or completely blocked by hydroxycitrate or 8-bromo-cGMP, respectively, which are agents interfering with palmitate metabolism (inhibiting lipid synthesis). The metabolic interaction between glucose and palmitate might generate lipid messengers (diacylglycerol, phosphatidylserine) necessary for the activation of islet protein kinase C, which would in turn result in a potentiation of glucose-induced insulin secretion.
Collapse
Affiliation(s)
- O Alcázar
- Department of Biochemistry, Complutense University Medical School, Madrid, Spain
| | | | | | | |
Collapse
|
38
|
Giné E, Gine E. [Empirical Processes and Applications: An Overview]: Rejoinder. BERNOULLI 1996. [DOI: 10.2307/3318567] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
|
39
|
Alcázar O, Giné E, Qiu-Yue Z, Tamarit-Rodríguez J. The stimulation of insulin secretion by D-glyceraldehyde correlates with its rate of oxidation in islet cells. Biochem J 1995; 310 ( Pt 1):215-20. [PMID: 7646447 PMCID: PMC1135875 DOI: 10.1042/bj3100215] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/26/2023]
Abstract
D-Glyceraldehyde's capacity to mimic the effect of D-glucose on insulin secretion has not yet been sufficiently substantiated. It has been recently proposed, however, that they might act through different mechanisms in insulin-secreting tumoral cells. Therefore, we have performed a dose-related study of both the secretory and metabolic effects of D-glyceraldehyde on islets, which have been compared with those produced by D-glucose. D-Glyceraldehyde's capacity to stimulate secretion was paralleled in a dose-dependent manner by its rate of oxidation to 14CO2. Partial inhibition of D-glyceraldehyde oxidation by beta-iodoacetamide resulted in a proportional decrease in the secretory response. L-Glyceraldehyde, which was apparently very poorly oxidized by islets, did not stimulate secretion. The ratio of the maximum insulin responses D-glyceraldehyde and D-glucose (57%) correlated with the ratio of their respective maximum rates of oxidation (68%). At sub-maximal concentrations there was a potentiation of the secretagogue effects of the hexose by the triose, which was not apparent at a maximum effective dose of glucose. It is concluded that D-glyceraldehyde mimics the secretory effect of glucose because, similarly to the hexose, it is metabolized through islet aerobic glycolysis. The lower potency of D-glyceraldehyde as an insulin secretagogue than D-glucose is determined by the lower capacity of islets to oxidize the triose compared with the hexose. D-Glyceraldehyde, unlike D-glucose, is metabolized in islets to D-lactate. Alternative routes for the metabolism of D-glyceraldehyde might explain some of the secretagogue differences between the triose and the hexose.
Collapse
Affiliation(s)
- O Alcázar
- Departamento de Bioquímica, Facultad de Medicina, Universidad Complutense, Madrid, Spain
| | | | | | | |
Collapse
|
40
|
Aldous D, Araujo A, Giné E, Gine E. The Central Limit Theorem for Real and Banach Valued Random Variables. Technometrics 1981. [DOI: 10.2307/1267796] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
|